Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAPtivate: DTX301 for OTC Deficiency
NCT02991144Phase 2Completed
- Sponsor
- Ultragenyx Pharmaceutical Inc.
- Start
- Jul 2017
- Primary completion
- Dec 2021
- Modality
- Gene Editing, Gene Silencing, AAV Vectors
- Countries
- 4
01
Overview
A Phase 2 trial of avalotcagene ontaparvovec in ornithine transcarbamylase deficiency, sponsored by Ultragenyx Pharmaceutical Inc.. Started Jul 2017; status: completed.
02
Drugs
avalotcagene ontaparvovec
03
Conditions
ornithine transcarbamylase deficiency
Beyond the preview
Go deeper on NCT02991144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02991144.